Patents by Inventor Michael Kalafatis
Michael Kalafatis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959110Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.Type: GrantFiled: January 25, 2021Date of Patent: April 16, 2024Assignee: Cleveland State UniversityInventors: Michael Kalafatis, Joseph Wiencek
-
Patent number: 11360077Abstract: Disclosed are methods and compositions for identifying and treating certain conditions and diseases. In certain instances, the general inventive concepts provide methods for determining rhTRAIL sensitivity of a sample and/or methods and compositions for inducing apoptosis to treat conditions and diseases with rhTRAIL.Type: GrantFiled: March 12, 2018Date of Patent: June 14, 2022Assignee: Cleveland State UniversityInventors: Michael Kalafatis, Katherine Turner
-
Publication number: 20210155918Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.Type: ApplicationFiled: January 25, 2021Publication date: May 27, 2021Inventors: Michael Kalafatis, Joseph Wiencek
-
Patent number: 10900027Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.Type: GrantFiled: October 7, 2016Date of Patent: January 26, 2021Assignee: Cleveland State UniversityInventors: Michael Kalafatis, Joseph Wiencek
-
Publication number: 20180348202Abstract: Disclosed are methods and compositions for identifying and treating certain conditions and diseases. In certain instances, the general inventive concepts provide methods for determining rhTRAIL sensitivity of a sample and/or methods and compositions for inducing apoptosis to treat conditions and diseases with rhTRAIL.Type: ApplicationFiled: March 12, 2018Publication date: December 6, 2018Inventors: Michael Kalafatis, Katherine Turner
-
Publication number: 20180305677Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.Type: ApplicationFiled: October 7, 2016Publication date: October 25, 2018Inventors: Michael Kalafatis, Joseph Wiencek
-
Publication number: 20100267638Abstract: Disclosed are an amino acid sequence of the human blood clotting factor Va, peptides containing such sequence, and additional peptides of interest that significantly inhibit thrombin generation. Also disclosed are pharmaceutical compositions containing these peptides and related therapeutic methods for inhibiting thrombin generation and treating blood coagulation disorders.Type: ApplicationFiled: March 9, 2010Publication date: October 21, 2010Applicant: CLEVELAND STATE UNIVERSITYInventor: Michael Kalafatis
-
Publication number: 20100048657Abstract: Methods and related compositions are disclosed for treating an array of myeloproliferative disorders and hematological malignancies. In particular, treatment methods and compositions for treating chronic myelogenous leukemia are disclosed. The methods and compositions utilize certain casein kinases, and specifically CK2? agents.Type: ApplicationFiled: September 11, 2007Publication date: February 25, 2010Applicant: CLEVELAND STATE UNIVERSITYInventor: Michael Kalafatis
-
Publication number: 20090054507Abstract: Inhibitors of casein kinase 2 are described that have been found to arrest uncontrolled cell proliferation, thereby suggesting their use in cancer treatment strategies. Specific applications include treating breast cancer, colon cancer, melanoma, chronic myelogenous leukemia, bladder cancer, renal cancer, and brain cancer. Various methods and compositions utilizing the inhibitors are described.Type: ApplicationFiled: August 29, 2008Publication date: February 26, 2009Applicant: CLEVELAND STATE UNIVERSITYInventor: Michael Kalafatis
-
Publication number: 20070299013Abstract: Disclosed are an amino acid sequence of the human blood clotting factor Va, peptides containing such sequence, and additional peptides of interest that significantly inhibit thrombin generation. Also disclosed are pharmaceutical compositions containing these peptides and related therapeutic methods for inhibiting thrombin generation and treating blood coagulation disorders.Type: ApplicationFiled: July 1, 2004Publication date: December 27, 2007Inventor: Michael Kalafatis
-
Patent number: 7074892Abstract: Peptides derived from amino acids 307 to 356 of the human blood coagulation factor Va are provided. Such peptides comprise: i) a length of between 3 and 50 amino acids, ii) a minimum of 3 contiguous amino acids from the 307–356 heavy chain region of factor Va, excluding peptide segments comprising amino acids 311 to 325 and amino acids 321 to 335, iii) optional additional amino acids at one or both ends of the contiguous amino acids such that the entire peptide is at least 60% identical to a sequence within 307 to 356 of factor Va, and iv) have an IC50 of between 50 nM to 500 ?M for inhibition of prothrombinase. The present invention also provides a pharmaceutical composition comprising one or more prothrombinase-inhibiting peptide segments. The present invention also provides administration of the pharmaceutical composition to human subjects for the purpose of preventing thrombotic disorders.Type: GrantFiled: March 8, 2004Date of Patent: July 11, 2006Assignee: Cleveland State UniversityInventors: Michael Kalafatis, Kenneth G. Mann
-
Publication number: 20040186271Abstract: Peptides derived from amino acids 307 to 356 of the human blood coagulation factor Va are provided. Such peptides comprise: i) a length of between 3 and 50 amino acids, ii) a minimum of 3 contiguous amino acids from the 307-356 heavy chain region of factor Va, excluding peptide segments comprising amino acids 311 to 325 and amino acids 321 to 335, iii) optional additional amino acids at one or both ends of the contiguous amino acids such that the entire peptide is at least 60% identical to a sequence within 307 to 356 of factor Va, and iv) have an IC50 of between 50 nM to 500 &mgr;M for inhibition of prothrombinase. The present invention also provides a pharmaceutical composition comprising one or more prothrombinase-inhibiting peptide segments. The present invention also provides administration of the pharmaceutical composition to human subjects for the purpose of preventing thrombotic disorders.Type: ApplicationFiled: March 8, 2004Publication date: September 23, 2004Inventors: Michael Kalafatis, Kenneth G. Mann
-
Patent number: 6703364Abstract: Peptides derived from amino acids 307 to 356 of the human blood coagulation factor Va are provided. Such peptides comprise: i) a length of between 3 and 50 amino acids, ii) a minimum of 3 contiguous amino acids from the 307-356 heavy chain region of factor Va, excluding peptide segments comprising amino acids 311 to 325 and amino acids 321 to 335, iii) optional additional amino acids at one or both ends of the contiguous amino acids such that the entire peptide is at least 60% identical to a sequence within 307 to 356 of factor Va, and iv) have an IC50 of between 50 nM to 500 &mgr;M for inhibition of prothrombinase. The present invention also provides a pharmaceutical composition comprising one or more prothrombinase-inhibiting peptide segments. The present invention also provides administration of the pharmaceutical composition to human subjects for the purpose of preventing thrombotic disorders.Type: GrantFiled: July 23, 2001Date of Patent: March 9, 2004Assignee: Cleveland State UniversityInventors: Michael Kalafatis, Kenneth G. Mann
-
Publication number: 20030040600Abstract: Peptides derived from amino acids 307 to 356 of the human blood coagulation factor Va are provided. Such peptides comprise: i) a length of between 3 and 50 amino acids, ii) a minimum of 3 contiguous amino acids from the 307-356 heavy chain region of factor Va, excluding peptide segments comprising amino acids 311 to 325 and amino acids 321 to 335, iii) optional additional amino acids at one or both ends of the contiguous amino acids such that the entire peptide is at least 60% identical to a sequence within 307 to 356 of factor Va, and iv) have an IC50 of between 50 nM to 500 &mgr;M for inhibition of prothrombinase. The present invention also provides a pharmaceutical composition comprising one or more prothrombinase-inhibiting peptide segments. The present invention also provides administration of the pharmaceutical composition to human subjects for the purpose of preventing thrombotic disorders.Type: ApplicationFiled: July 23, 2001Publication date: February 27, 2003Inventors: Michael Kalafatis, Kenneth Mann
-
Patent number: 6248548Abstract: Persons having the Factor VLEIDEN mutation and a lower than average plasma level of TFPI have been found to be at elevated risk of thrombosis. Prophylactic methods for reducing the risk of thrombosis employ the administration of TFPI to achieve higher levels in the plasma.Type: GrantFiled: November 1, 1999Date of Patent: June 19, 2001Assignee: The University of Vermont and State Agriculture CollegeInventors: Cornelis Van't Veer, Michael Kalafatis, Kenneth G. Mann
-
Patent number: 5977057Abstract: Persons having the Factor V.sup.LEIDEN mutation and a lower than average plasma level of TFPI have been found to be at elevated risk of thrombosis. Prophylactic methods for reducing the risk of thrombosis employ the administration of TFPI to achieve higher levels in the plasma.Type: GrantFiled: May 8, 1996Date of Patent: November 2, 1999Assignee: The University of Vermont and State Agricultural CollegeInventors: Cornelis Van't Veer, Michael Kalafatis, Kenneth G. Mann
-
Patent number: 5856114Abstract: The present invention is directed to immunochemical detection procedures, e.g., using both Western blotting and direct immunoassays, for fragments of Factor Va, which can thus be used; (a) in a predictive manner to evaluate the existence and/or extent of a thrombotic complication; (b) to monitor the efficacy of prophylaxis for a thrombotic condition; and (c) as a means to evaluate potential risk of hemorrhage during thrombolytic therapy.Type: GrantFiled: February 26, 1996Date of Patent: January 5, 1999Assignee: The University of VermontInventors: Kenneth G. Mann, Michael Kalafatis